Brief: Atara Biotherapeutics Announces Primary Analysis Data From Phase 2 EMBOLD Clinical Trial Of ATA188 In Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics

08/11/2023 23:09

Nov 8 (Reuters) - Atara Biotherapeutics Inc  ATRA.O :
    * ATARA BIOTHERAPEUTICS ANNOUNCES PRIMARY ANALYSIS DATA FROM
PHASE
2 EMBOLD CLINICAL TRIAL OF ATA188 IN NON-ACTIVE PROGRESSIVE
MULTIPLE SCLEROSIS
    * ATARA BIOTHERAPEUTICS INC - PRIMARY ENDPOINT OF CONFIRMED
DISABILITY IMPROVEMENT AT 12 MONTHS NOT ACHIEVED
    * ATARA BIOTHERAPEUTICS INC - COMPANY TO FURTHER ANALYZE
DATA AND
EVALUATE STRATEGIC OPTIONS FOR ATA188 PROGRAM
    * ATARA BIOTHERAPEUTICS INC - FOCUSING OF RESOURCES AND
PLANNED
EXPENSE REDUCTIONS EXPECTED TO EXTEND CASH RUNWAY BEYOND Q3 2025
    * ATARA BIOTHERAPEUTICS INC - ALLOGENEIC CAR-T PORTFOLIO
ADVANCING
WITH SEVERAL CATALYSTS ANTICIPATED IN NEXT 18 MONTHS

Source text for Eikon:  ID:nBwbl8HnZa 
Further company coverage:  ATRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))